Longevity & AgingRJx-01 Phase 2 Trial Targets Muscle Loss With Multi-Pathway Drug Approach
Rejuvenate Biomed has finished enrolling 198 participants across Europe and the UK in a Phase 2 trial of RJx-01, a drug designed to fight muscle loss caused by COPD. Sarcopenia — the progressive loss of muscle mass and strength — affects millions of older adults and currently has no approved drug treatments. Unlike previous experimental approaches that targeted a single mechanism, RJx-01 simultaneously addresses mitochondrial dysfunction, inflammation, and fibrosis. Early Phase 1 data showed improvements in both biological markers and physical muscle performance. Topline results are expected by end of 2026, and if successful, this trial could open a regulatory pathway that bridges aging biology with mainstream medicine.
